Shopping Cart
- Remove All
Your shopping cart is currently empty
Vipivotide tetraxetan (PSMA-617) is a highly potent inhibitor of prostate-specific membrane antigen (PSMA) with a Ki of 0.37 nM.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $193 | In Stock | |
| 2 mg | $287 | In Stock | |
| 5 mg | $483 | In Stock | |
| 10 mg | $691 | In Stock | |
| 25 mg | $1,080 | In Stock | |
| 50 mg | $1,490 | In Stock | |
| 100 mg | $1,960 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $1,190 | In Stock |
| Description | Vipivotide tetraxetan (PSMA-617) is a highly potent inhibitor of prostate-specific membrane antigen (PSMA) with a Ki of 0.37 nM. |
| Targets&IC50 | PSMA:0.37 nM (Ki), LNCaP cells:2.34 - 2.94 nM (Ki) |
| In vitro | The chemically modified PSMA inhibitor PSMA-617 demonstrated high radiolytic stability for at least 72 h. A high inhibition potency (equilibrium dissociation constant [K(i)] = 2.34 2.94 nM on LNCaP; K(i) = 0.37 0.21 nM enzymatically determined) and highly efficient internalization into LNCaP cells were demonstrated. |
| In vivo | The small-animal PET measurements showed high tumor-to-background contrasts as early as 1 h after injection of Vipivotide tetraxetan.Organ distribution revealed specific uptake in LNCaP tumors and in the kidneys 1 h after injection of Vipivotide tetraxetan[1]. |
| Synonyms | PSMA-617 |
| Molecular Weight | 1042.14 |
| Formula | C49H71N9O16 |
| Cas No. | 1702967-37-0 |
| Smiles | OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@H]1CC[C@H](CNC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)CC1)C(O)=O)C(O)=O |
| Relative Density. | 1.322 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (95.96 mM), Sonication is recommended. H2O: 100 mg/mL (95.96 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (3.84 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO/H2O
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.